Digital Therapeutics (DTx) represent a new class of evidence-based therapeutic interventions delivered through software to prevent, manage, or treat mental health disorders. In the UK, these tools are increasingly being prescribed alongside or instead of traditional pharmacological treatments for conditions such as insomnia, anxiety, and depression. The rigor of the UK’s regulatory environment ensures that these digital treatments undergo clinical trials, providing clinicians with the confidence to incorporate them into standard care pathways.

Research into the UK Digital Mental Health Market indicates that the prescriptive model of digital health is gaining traction. By utilizing Virtual Reality (VR) for exposure therapy or gamified apps for neurodevelopmental disorders, healthcare providers can offer highly engaging and effective treatments. This clinical integration is supported by a robust reimbursement landscape, where the NHS is increasingly funding digital prescriptions through specialized commissioning routes. As the evidence base for DTx continues to grow, these digital treatments are expected to become a staple of the UK’s approach to mental healthcare.